NCT03375567View on ClinicalTrials.gov

Global Response Assessment by Advanced Imaging and Myeloma Lesion Biopsies During Induction Therapy of Multiple Myeloma With Carfilzomib Lenalidomide Dexamethasone

NACompletedINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

June 4, 2018

Primary Completion Date

January 14, 2022

Study Completion Date

January 14, 2022

Conditions
Multiple Myeloma
Interventions
PROCEDURE

Guided Lesion Biopsies

After patients are treated with Carfilzomib Lenalidomide Dexamethasone (CRD), lesion biopsies will be performed per usual care. Patients will have biopsies performed on lesions using a novel image guided technique.

PROCEDURE

Standard Lesion Biopsies

After patients are treated with Carfilzomib Lenalidomide Dexamethasone (CRD), lesion biopsies will be performed per usual care. Patients will have biopsies performed on lesions using a novel image guided technique.

Trial Locations (1)

06520-8028

Yale Cancer Center, New Haven

All Listed Sponsors
lead

Yale University

OTHER

NCT03375567 - Global Response Assessment by Advanced Imaging and Myeloma Lesion Biopsies During Induction Therapy of Multiple Myeloma With Carfilzomib Lenalidomide Dexamethasone | Biotech Hunter | Biotech Hunter